Gilead's Single-Tablet HIV Regimen Matches Complex Multi-Pill Therapies in Two Phase 3 Trials, Lancet Reports
Two Phase 3 ARTISTRY trials show bictegravir/lenacapavir maintains viral suppression while replacing regimens of up to 11 daily pills with one tablet.
Overview
Gilead Sciences has published Phase 3 results from two large clinical trials demonstrating that a single-tablet combination of bictegravir and lenacapavir (BIC/LEN) can maintain HIV viral suppression as effectively as the complex multi-drug regimens and guideline-recommended treatments it is designed to replace. The ARTISTRY-1 results were published in The Lancet on February 25, 2026, with both trials presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2026. If approved, the combination would allow patients currently taking as many as 11 pills per day to switch to a single daily tablet.
What We Know
The two trials tested BIC/LEN in different patient populations. ARTISTRY-1, a Phase 2/3 multicenter trial, enrolled adults with HIV who were virologically suppressed on complex multi-tablet regimens, with some participants taking between 2 and 11 pills daily and approximately 40 percent dosing multiple times per day. Participants were randomized 2:1 to switch to BIC/LEN or continue their existing regimen, according to Gilead’s press release on BusinessWire.
At week 48, the BIC/LEN group showed 0.8 percent of participants with detectable HIV-1 RNA at or above 50 copies per milliliter, compared with 1.1 percent in the group that remained on their complex regimens. The combination met its primary endpoint of non-inferiority, as reported by BusinessWire.
ARTISTRY-2, a Phase 3 double-blind randomized trial, compared BIC/LEN head-to-head against Biktarvy, Gilead’s own blockbuster single-tablet regimen that is currently the most widely prescribed HIV treatment globally. Through week 48, 1.3 percent of BIC/LEN participants had detectable virus compared to 1.0 percent in the Biktarvy arm, again meeting non-inferiority, according to BusinessWire.
On safety, BIC/LEN was generally well tolerated across both trials. In ARTISTRY-1, drug-related adverse events occurred in 14.3 percent of participants who switched to BIC/LEN compared to 1.6 percent in the complex regimen group, though serious adverse events were rare at 0.3 percent versus zero. In ARTISTRY-2, drug-related adverse events were comparable between arms at 10.4 percent for BIC/LEN and 12.0 percent for Biktarvy, with no serious adverse events reported, according to BusinessWire. No emergent drug resistance was observed in ARTISTRY-1, and only one isolated integrase substitution without phenotypic resistance was detected in the ARTISTRY-2 BIC/LEN group, with no capsid mutations found.
Chloe Orkin, a researcher involved in the trials, stated that “finding new effective and convenient dosing with single-tablet regimens is key to optimizing treatment,” as reported by BusinessWire.
What We Don’t Know
Gilead has stated that these results will inform regulatory filings, but no specific submission timeline has been disclosed. The long-term safety and efficacy of BIC/LEN beyond 48 weeks remain to be established through ongoing follow-up. It is also unclear how the combination’s pricing will compare to Biktarvy, which generated approximately $13.5 billion in revenue for Gilead in 2025, or whether payers will broadly cover a switch from regimens that already achieve viral suppression.
The higher rate of drug-related adverse events in the BIC/LEN arm of ARTISTRY-1 (14.3 percent versus 1.6 percent) warrants attention, even though serious events were rare. Whether this gap narrows with longer exposure or reflects the adjustment period inherent to switching regimens has not yet been clarified.
Analysis
The ARTISTRY trials are strategically significant for Gilead on two fronts. First, they address a genuine clinical need: an estimated 20 to 30 percent of people living with HIV still take multi-tablet, multi-dose regimens, often because of resistance mutations, drug interactions, or comorbidities that preclude simpler options. Consolidating these complex regimens into a single daily pill could meaningfully improve adherence and quality of life for this population.
Second, the trials position BIC/LEN as a successor to Biktarvy, whose U.S. patent exclusivity is projected to expire in the coming years. By combining bictegravir, an established integrase inhibitor, with lenacapavir, a first-in-class capsid inhibitor already approved for multi-drug-resistant HIV, Gilead is building a next-generation backbone that could extend its dominance in the HIV treatment market. The Lancet publication and CROI presentation lend clinical credibility to what is also a commercial imperative.